MentionFox
Home › Executive changes › Protagenic Therapeutics, Inc.\new
Leadership changes · PTIX · SEC Form 8-K, Item 5.02

Leadership changes at Protagenic Therapeutics, Inc.\new (2026)

Before you join, sell to or invest in Protagenic Therapeutics, Inc.\new

MentionFox check on Protagenic Therapeutics, Inc.\new: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/protagenic-therapeutics-inc-new

Check Protagenic Therapeutics, Inc.\new before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Protagenic Therapeutics, Inc.\new?

Who joined and who left Protagenic Therapeutics, Inc.\new (PTIX)? 2 filings reported from 2026-03-03 to 2026-04-07, each cited to the company's own filing.

As of November 14, 2026, Protagenic Therapeutics, Inc.\new has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from March 3, 2026 to April 7, 2026 (Form 8-K, April 7, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

BIGGER CAPITAL FUND L P also filed stake reports on 13 other companies ↓

Sell to companies like Protagenic Therapeutics, Inc.\new? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes2
Latest filing2026-04-07

Protagenic Therapeutics, Inc.\new reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-03-03 to 2026-04-07. Every row below is cited to the filing it comes from, and this page adds each new change as Protagenic Therapeutics, Inc.\new files it.

Also on the record for Protagenic Therapeutics, Inc.\new

DateRecordFigureOur pageSource
August 25, 2025Stake report, Schedule 13G/A, by BIGGER CAPITAL FUND L P—5%+ stakesSource
July 8, 2025Stake report, Schedule 13G, by BIGGER CAPITAL FUND L P5.75% of the class5%+ stakesSource

Selling to them or working with them? See who runs Protagenic Therapeutics, Inc.\new now and the warning signs.

Watch Protagenic Therapeutics, Inc.\new: email me the next time it files something

Free to see. No signup.

Keep reading

More on Protagenic Therapeutics, Inc.\new and the records around it.

Companies that share a holder

Want the whole picture on Protagenic Therapeutics, Inc.\new?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Protagenic Therapeutics, Inc.\new: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Protagenic Therapeutics, Inc.\new covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    4 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-04-07Reportednot named in the filing8-K, 2026-04-07
2026-03-03Reportednot named in the filing8-K, 2026-03-03
Selling to Protagenic Therapeutics, Inc.\new?

New leaders reset buying decisions — get the Full Report on Protagenic Therapeutics, Inc.\new: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Protagenic Therapeutics, Inc.\new

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Protagenic Therapeutics, Inc.\new, with the record behind each one.

Find candidates like senior executive at Protagenic Therapeutics, Inc.\new

Every change, in the filing's words

Filed 2026-04-07 · 8-K

Reported

On March 31, 2026, the Board of Directors of Protagenic Therapeutics, Inc. (the "Company") notified Alexander Arrow, MD, the Company's Chief Financial Officer, that his employment with the Company will be terminated effective April 30, 2026.
Filed 2026-03-03 · 8-K

Reported

On February 3, 2026, the Board of Directors (the "Board") of Protagenic Therapeutics, Inc. (the "Company") appointed William (Bill) Nichols, Jr., age 51, as President of the Company.

Also stated in this filing

  • During the past five years, Mr. Nichols has held senior commercial leadership roles at bluebird bio, a biotechnology company, and previously held senior commercial leadership roles at Dova Pharmaceuticals (now Sobi) and Bristol-Myers Squibb, each a biopharmaceutical company.
  • Under the terms of his employment agreement, Mr. Nichols will receive an annual base salary of $350,000 and will be eligible for an annual target bonus equal to 40% of his base salary.
  • The employment agreement also contemplates an option grant equal to approximately 1.0% of the Company's fully diluted share count.

Tools for this story

Each opens in a new tab, filled in for Protagenic Therapeutics, Inc.\new. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/protagenic-therapeutics-inc-new
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Leadership changes at Protagenic Therapeutics, Inc.\new (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/protagenic-therapeutics-inc-new